Lee Jacks 4

4 · Vaxcyte, Inc. · Filed Jun 16, 2026

AI-generated summary of this filing

Updated Jun 16, 2026

Vaxcyte (PCVX) Director Lee Jacks Receives Award

What Happened

Lee Jacks, a director of Vaxcyte, received equity awards on June 15, 2026: 2,265 shares granted (no cash paid) and 11,389 derivative awards recorded at $0.00. These are grants/awards (not open-market purchases or sales).

Key Details

Transaction date: June 15, 2026; Form 4 filed June 16, 2026 (timely filing).
Grants: 2,265 shares acquired @ $0.00; 11,389 derivative units acquired @ $0.00.
Shares owned after the transaction: not specified in the provided excerpt of the filing.
Footnotes: F1 describes RSUs (each RSU = right to receive one share) that vest on the earlier of June 15, 2027 or the day before the next annual meeting, subject to acceleration and continuous service. F2 indicates certain shares subject to an option that vest monthly and fully vest on the same schedule.
No sale or cash exercise reported; these are compensation awards.

Context

These awards are compensation-related grants rather than purchases — RSUs are contingent rights to receive shares upon vesting, and options (if applicable) vest monthly before they can be exercised. Such grants are common for directors and do not by themselves indicate intent to buy or sell stock in the market.

Form 4

Period: 2026-06-15

Director

Transactions

Award
Common Stock
[F1]
2026-06-15+2,265→ 6,856 total
Award
Stock Option (right to buy)
[F2]
2026-06-15+11,389→ 11,389 total
Exercise: $49.56Exp: 2036-06-15→ Common Stock (11,389 underlying)

Footnotes (2)

[F1]Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
[F2]The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Signature

Jacks Lee, by /s/ Peter N. Efremenko, Attorney-In-Fact|2026-06-16

1 file